Update on the treatment of ankylosing spondylitis

References

• AsklingJForedCMGeborekPSwedish registers to examine drug safety and clinical issues in RAAnn Rheum Dis2006657071216414975
   PubMed Web of Science ®Google Scholar
• AsklingJForedCMBaecklundEHaematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonistsAnn Rheum Dis20056414142015843454
   PubMed Web of Science ®Google Scholar
• AsklingJForedCMBrandtLRisks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonistsAnn Rheum Dis2005641421615829572
   PubMed Web of Science ®Google Scholar
• BaraliakosXDavisJTsujiWMagnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanerceptArthritis Rheum20055212162315818694
   PubMed Web of Science ®Google Scholar
• BaraliakosXListingJBrandtJClinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3-years of continuous treatment with infliximabArthritis Res Therapy20057R4394
   PubMed Web of Science ®Google Scholar
• BaughmanRPDrentMKavuruMInfliximab therapy in patients with chronic sarcoidosis and pulmonary involvementAm J Respir Crit Care Med200617479580216840744
   PubMed Web of Science ®Google Scholar
• BaughmanRPLowerEEBradleyDAEtanercept for refractory ocular sarcoidosis: results of a double-blind randomized trialChest200512810624716100213
   PubMed Web of Science ®Google Scholar
• BongartzTSuttonAJSweetingMJAnti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trialsJAMA200629522758516705109
   PubMed Web of Science ®Google Scholar
• BraunJBaraliakosXBrandtJPersistent clinical response to the anti-TNF-a antibody infliximab in patients with ankylosing spondylitis over 3-yearsRheumatol2005446706
   PubMed Web of Science ®Google Scholar
• BraunJBaraliakosXGolderWImprovement of spinal inflammation in ankylosing spondylitis (AS) by infliximab therapy as assessed by magnetic resonance imaging (MRI) using a novel evaluated spinal scoring systemArthritis Rheum20034811263612687557
   PubMed Web of Science ®Google Scholar
• BraunJBaraliakosXListingJDecreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanerceptArthritis Rheum20055224475316052578
   PubMed Web of Science ®Google Scholar
• BraunJBrandtJListingJTreatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trialLancet200235911879311955536
   PubMed Web of Science ®Google Scholar
• BraunJLandeweRHermannKGMajor reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging studyArthritis Rheum20065416465216646033
   PubMed Web of Science ®Google Scholar
• BraunJPhamTSieperJInternational ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitisAnn Rheum Dis2003628172412922952
   PubMed Web of Science ®Google Scholar
• BraunJZochlingJBaraliakosXEfficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondy-loarthritis and early ankylosing spondylitis: a multicentre randomised controlled trialAnn Rheum Dis20066511475316606646
   PubMed Web of Science ®Google Scholar
• BrebanMRavaudPClaudepierrePNo superiority of infliximab (INF) plus methotrexate (MTX) over INF alone in the treatment of ankylosing spondylitis (AS): results of a one-year randomized prospective studyArthritis Rheum200552Suppl498
   Google Scholar
• ChenJLiuCIs sulphasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trialsJ Rheumatol2006337223116583475
   PubMed Web of Science ®Google Scholar
• CleggDORedaDJWeismanMHComparison of sulfasalazine and placebo in the treatment of ankylsoing spondylitisArthritis Rheum1996392004128961905
   PubMed Web of Science ®Google Scholar
• Cobo-IbáñezTMuñoz-FernándezSBohorquez-HerasCNew acute anterior uveitis flares in patients with spondyloarthropathies treated with TNF blockersArthritis Rheum200654Suppl 91118
   Google Scholar
• CreemersMCWFranssenMJAMvan’t HofMAA radiographic scoring system and identification of variables measuring structural damage in ankylosing spondylitis [thesis]1994Nijmegen, The NetherlandsUniversity of Nijmegen
   Google Scholar
• DavisJCvan der HeijdeDBraunJRecombinant human tumor necrosis factor receptor (Etanercept) for treating ankylosing spondylitisArthritis Rheum2003483230614613288
   PubMed Web of Science ®Google Scholar
• DavisJCvan der HeijdeDMBraunJSustained durability and tolerability of etanercept in ankylosing spondylitis for 96-weeksAnn Rheum Dis20056415576215843448
   PubMed Web of Science ®Google Scholar
• DavisJCJrVan der HeijdeDMDougadosMBaseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanerceptJournal of Rheumatol20053217514
   PubMed Web of Science ®Google Scholar
• DixonWGWatsonKLuntMBritish Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics RegisterArthritis Rheum20065423687616868999
   PubMed Web of Science ®Google Scholar
• DougadosMvan der LindenSLeirisalo-RepoMSulfasalazine in the treatment of spondyloarthropathyArthritis Rheum199538618277748217
   PubMed Web of Science ®Google Scholar
• Gonzalez-LopezMABlancoRGonzalez-VelaMCDevelopment of sarcoidosis during etanercept therapyArthritis Rheum2006558172017013853
   PubMed Web of Science ®Google Scholar
• GuignardSGossecLSalliotCEfficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective studyAnn Rheum Dis2006651631416901960
   PubMed Web of Science ®Google Scholar
• HaibelHRudwaleitMBrandtHCAdalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trialArthritis Rheum2006546788116447247
   PubMed Web of Science ®Google Scholar
• HanauerSBSandbornWJRutgeertsPHuman anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trialGastroenterol200613032333
   PubMed Web of Science ®Google Scholar
• InmanRDShojaniaKKeystoneEEfficacy of lower dose infliximab in active ankylosing spondylitis – interim results of a Canadian studyArthritis Rheum200654(Suppl 9)S471
   Google Scholar
• JacobssonLTTuressonCGulfeATreatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritisJ Rheumatol20053212131815996054
   PubMed Web of Science ®Google Scholar
• LambertRGWSalonenDRahmanPAdalimumab reduces spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis (AS) – 52-week magnetic resonance imaging (MRI) results from The Canadian AS StudyAnn Rheum Dis200665Suppl 1165
   Google Scholar
• ListingJStrangfeldAKarySInfections in patients with rheumatoid arthritis treated with biologic agentsArthritis Rheum20055234031216255017
   PubMed Web of Science ®Google Scholar
• MaksymowychWPInmanRDGladmanDCanadian Rheumatology Association consensus on the use of anti-TNF(-directed therapies in the treatment of spondyloarthritisJ Rheumatol20033013566312784417
   PubMed Web of Science ®Google Scholar
• MaksymowychWPInmanRDSalonenDSpondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitisArthritis Rheum2005a53502916082639
   PubMed Web of Science ®Google Scholar
• MaksymowychWPInmanRDSalonenDSpondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitisArthritis Rheum2005b53703916208659
   PubMed Web of Science ®Google Scholar
• MaksymowychWPLandewèRConner-SpadyBSerum Matrix Metalloproteinase 3 is an Independent Predictor of Structural Damage Progression in Patients with Ankylosing Spondylitis (AS)Arthritis Rheum200654Suppl 9S512
   Google Scholar
• MaksymowychWPPatraKInmanRDAdalimumab suppresses biomarkes of cartilage degradation in active ankylosing spondylitis – results of the Canada AS studyArthritis Rheum200553Suppl 9L6
   Google Scholar
• MaksymowychWPPooleARHiebertLEtanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitisJ Rheumatol2005321911716206346
   PubMed Web of Science ®Google Scholar
• MaksymowychWPRahmanPKeystoneEEfficacy of adalimumab in active ankylosing spondylitis (AS) (Results of the Canadian AS StudyArthritis Rheum200552SupplS217
   Google Scholar
• NealBRodgersADunnLFransenMNon-steroidal antiinflammatory drugs for preventing heterotopic bone formation after hip arthroplastyCochrane Database Syst Rev20003CD00116010908488
   PubMedGoogle Scholar
• NissilaMLehtinenKLeirisalo-RepoMSulfasalazine in the treatment of ankylosing spondylitisArthritis Rheum1988311111162901839
   PubMed Web of Science ®Google Scholar
• OhJArkfeldDGHorwitzDADevelopment of Crohn’s disease in a patient taking etanerceptJ Rheumatol200532752315801037
   PubMed Web of Science ®Google Scholar
• PhamTLandeweRvan der LindenSAn international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitisAnn Rheum Dis2006651620516464984
   PubMed Web of Science ®Google Scholar
• RudwaleitMListingJBrandtJPrediction of a major clinical response (BASDAI 50) to tumour necrosis factor a blockers in ankylosing spondylitisAnn Rheum Dis2004636657015037444
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBKatzSEtanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trialGastroenterol2001121108894
   PubMed Web of Science ®Google Scholar
• SetoguchiSSolomonDHWeinblattMETumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritisArthritis Rheum20065427576416947774
   PubMed Web of Science ®Google Scholar
• SiegleIKleinTBackmanJTExpression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseasesArthritis Rheum19984112299433877
   PubMed Web of Science ®Google Scholar
• TarganSRHanauerSBvan DeventerSJA short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study GroupN Enl J Med1997337102935
   PubMed Web of Science ®Google Scholar
• UtzJPLimperAHKalraSEtanercept for the treatment of stage II and III progressive pulmonary sarcoidosisChest20031241778512853521
   PubMed Web of Science ®Google Scholar
• van der HeijdeDBarafHSBRamos-RemusCEvaluation of the efficacy of etoricoxib in ankylosing spondylitisArthritis Rheum20055212051515818702
   PubMed Web of Science ®Google Scholar
• van der HeijdeDDijkmansBGeusensPEfficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized placebo-controlled trial (ASSERT)Arthritis Rheum2005525829115692973
   PubMed Web of Science ®Google Scholar
• van der HeijdeDKivitzAEfficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trialArthritis Rheum20065421364616802350
   PubMed Web of Science ®Google Scholar
• van der HeijdeDLandeweRvan der LindenSHow should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measuredArthritis Rheum20055219798515986341
   PubMed Web of Science ®Google Scholar
• van der HeijdeDMLandeweROryPTwo-year etanercept therapy does not inhibit radiographic progression in patients with ankylosing spondylitisAnn Rheum Dis200665Suppl II8115919677
   PubMed Web of Science ®Google Scholar
• van der HeijdeDMFMWandersAMielantsHPrediction of progression of radiographic damage over 4-years in patients with ankylosing spondylitisAnn Rheum Dis200463OP132
   Web of Science ®Google Scholar
• WandersAvan der HeijdeDLandeweRNonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized controlled trialArthritis Rheum20055217566515934081
   PubMed Web of Science ®Google Scholar
• WandersAJBLandewe’RBMSpoorenbergAWhat is the most appropriate radiologic scoring method for ankylosing spondylitisArthritis Rheum20045026223215334477
   PubMed Web of Science ®Google Scholar
• ZhangXSchwarzEMYoungDACyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repairJ Clin Invest200210914051512045254
   PubMed Web of Science ®Google Scholar